Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

por Cooper, Zachary A., Frederick, Dennie T., Ahmed, Zain, Wargo, Jennifer A.
Publicado 2013

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

por Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
Publicado 2015

Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma

por Romano, David, García-Gutiérrez, Lucía, Aboud, Nourhan, Duffy, David J, Flaherty, Keith T, Frederick, Dennie T, Kolch, Walter, Matallanas, David
Publicado 2022

BAP1 PLAYS A SURVIVAL ROLE IN CUTANEOUS MELANOMA

por Kumar, Raj, Taylor, Michael, Miao, Benchun, Ji, Zhenyu, Njauw, Jenny Ching-Ni, Jönsson, Göran, Frederick, Dennie Tompers, Tsao, Hensin
Publicado 2014

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma

por Rauwerdink, Daan Jan Willem, Molina, George, Frederick, Dennie Tompers, Sharova, Tanya, van der Hage, Jos, Cohen, Sonia, Boland, Genevieve Marie
Publicado 2020

Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants

por Stopfer, Lauren E., Gajadhar, Aaron S., Patel, Bhavin, Gallien, Sebastien, Frederick, Dennie T., Boland, Genevieve M., Sullivan, Ryan J., White, Forest M.
Publicado 2021

Low expression of the PPARγ-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases

por Meylan, Patrick, Pich, Christine, Winkler, Carine, Ginster, Stefanie, Mury, Lionel, Sgandurra, Marie, Dreos, René, Frederick, Dennie Tompers, Hammond, Marc, Boland, Genevieve Marie, Michalik, Liliane
Publicado 2021

MITF Modulates Therapeutic Resistance through EGFR Signaling

por Ji, Zhenyu, Chen, Yiyin Erin, Kumar, Raj, Taylor, Michael, Njauw, Ching-Ni Jenny, Miao, Benchun, Frederick, Dennie T., Wargo, Jennifer A., Flaherty, Keith T., Jönsson, Göran, Tsao, Hensin
Publicado 2015

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

por Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Publicado 2013

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

por Johannessen, Cory M., Johnson, Laura A., Piccioni, Federica, Townes, Aisha, Frederick, Dennie T., Donahue, Melanie K., Narayan, Rajiv, Flaherty, Keith T., Wargo, Jennifer A., Root, David E., Garraway, Levi A.
Publicado 2013

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

por Sabbatino, Francesco, Wang, Yangyang, Wang, Xinhui, Flaherty, Keith T., Yu, Ling, Pepin, David, Scognamiglio, Giosue', Pepe, Stefano, Kirkwood, John M., Cooper, Zachary A., Frederick, Dennie T., Wargo, Jennifer A., Ferrone, Soldano, Ferrone, Cristina R.
Publicado 2014

Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma

por Du, Kuang, Wei, Shiyou, Wei, Zhi, Frederick, Dennie T., Miao, Benchun, Moll, Tabea, Tian, Tian, Sugarman, Eric, Gabrilovich, Dmitry I., Sullivan, Ryan J., Liu, Lunxu, Flaherty, Keith T., Boland, Genevieve M., Herlyn, Meenhard, Zhang, Gao
Publicado 2021

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

por Shen, Che-Hung, Kim, Sun Hye, Trousil, Sebastian, Frederick, Dennie T., Piris, Adriano, Yuan, Ping, Cai, Li, Gu, Lei, Li, Man, Lee, Jung Hyun, Mitra, Devarati, Fisher, David E., Sullivan, Ryan J., Flaherty, Keith T., Zheng, Bin
Publicado 2016

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

por Pickering, Chad, Aiyetan, Paul, Xu, Gege, Mitchell, Alan, Rice, Rachel, Najjar, Yana G., Markowitz, Joseph, Ebert, Lisa M., Brown, Michael P., Tapia-Rico, Gonzalo, Frederick, Dennie, Cong, Xin, Serie, Daniel, Lindpaintner, Klaus, Schwarz, Flavio, Boland, Genevieve M.
Publicado 2023

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome

por Shi, Alvin, Kasumova, Gyulnara G., Michaud, William A., Cintolo-Gonzalez, Jessica, Díaz-Martínez, Marta, Ohmura, Jacqueline, Mehta, Arnav, Chien, Isabel, Frederick, Dennie T., Cohen, Sonia, Plana, Deborah, Johnson, Douglas, Flaherty, Keith T., Sullivan, Ryan J., Kellis, Manolis, Boland, Genevieve M.
Publicado 2020

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohor...

por Bai, Xue, Kim, Michelle, Kasumova, Gyulnara, Si, Lu, Tang, Bixia, Cui, Chuanliang, Yang, Xiaoling, Wei, Xiaoting, Cohen, Justine, Lawrence, Donald, Freedman, Christine, Fadden, Riley, Rubin, Krista, Sharova, Tatyana, Frederick, Dennie, Flaherty, Keith, Sullivan, Ryan, Guo, Jun, Boland, Genevieve
Publicado 2021

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

por Smith, Michael P., Brunton, Holly, Rowling, Emily J., Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L., Girotti, Maria R., Marais, Richard, Levesque, Mitchell P., Dummer, Reinhard, Frederick, Dennie T., Flaherty, Keith T., Cooper, Zachary A., Wargo, Jennifer A., Wellbrock, Claudia
Publicado 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

por Friedman, Adam A., Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Baniya, Subash, Cooper, Zachary A., Piris, Adriano, Hargreaves, Leeza, Igras, Vivien, Frederick, Dennie T., Lawrence, Donald P., Haber, Daniel A., Flaherty, Keith T., Wargo, Jennifer A., Ramaswamy, Sridhar, Benes, Cyril H., Fisher, David E.
Publicado 2015

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

por Young, Helen L., Rowling, Emily J., Bugatti, Mattia, Giurisato, Emanuele, Luheshi, Nadia, Arozarena, Imanol, Acosta, Juan-Carlos, Kamarashev, Jivko, Frederick, Dennie T., Cooper, Zachary A., Reuben, Alexandre, Gil, Jesus, Flaherty, Keith T., Wargo, Jennifer A., Vermi, William, Smith, Michael P., Wellbrock, Claudia, Hurlstone, Adam
Publicado 2017

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

por Frederick, Dennie T., Salas Fragomeni, Roberto A., Schalck, Aislyn, Ferreiro-Neira, Isabel, Hoff, Taylor, Cooper, Zachary A., Haq, Rizwan, Panka, David J., Kwong, Lawrence N., Davies, Michael A., Cusack, James C., Flaherty, Keith T., Fisher, David E., Mier, James W., Wargo, Jennifer A., Sullivan, Ryan J.
Publicado 2014